Warning letter
Surmasis Pharmaceutical: warning letter of Nov 6, 2018
FDA warning letter 553686 · Detroit District Office
Key facts
| Reference number | 553686 |
|---|---|
| Company | Surmasis Pharmaceutical |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Nov 6, 2018 |
| Posted date | Nov 6, 2018 |
| Issuing office | Detroit District Office |
| Product type | Drugs |
| CFR sections cited | 211.192, 211.188, 211.194(a) |
| Inspection city | Des Moines |
| Inspection ZIP | 50321 |
| Inspection start date | Feb 12, 2018 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: